SGEN
Price:
$228.74
Market Cap:
$43.15B
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic b...[Read more]
Industry
Biotechnology
IPO Date
2001-03-09
Stock Exchange
NASDAQ
Ticker
SGEN
According to Seagen Inc.’s latest financial reports and current stock price. The company's current ROE is -16.53%. This represents a change of 134.18% compared to the average of -7.06% of the last 4 quarters.
The mean historical ROE of Seagen Inc. over the last ten years is -16.85%. The current -16.53% ROE has changed -1.88% with respect to the historical average. Over the past ten years (40 quarters), SGEN's ROE was at its highest in in the September 2020 quarter at 28.17%. The ROE was at its lowest in in the June 2015 quarter at -26.45%.
Average
-16.85%
Median
-20.15%
Minimum
-36.11%
Maximum
17.59%
Discovering the peaks and valleys of Seagen Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 32.96%
Maximum Annual ROE = 17.59%
Minimum Annual Increase = -621.97%
Minimum Annual ROE = -36.11%
Year | ROE | Change |
---|---|---|
2022 | -21.77% | -1.08% |
2021 | -22.00% | -225.07% |
2020 | 17.59% | -621.97% |
2019 | -3.37% | -80.72% |
2018 | -17.48% | -5.65% |
2017 | -18.53% | -16.16% |
2016 | -22.10% | 25.79% |
2015 | -17.57% | -51.36% |
2014 | -36.11% | 32.96% |
2013 | -27.16% | 14.21% |
The current ROE of Seagen Inc. (SGEN) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-8.73%
5-year avg
-9.41%
10-year avg
-16.85%
Seagen Inc.’s ROE is less than BioMarin Pharmaceutical Inc. (6.22%), less than Alnylam Pharmaceuticals, Inc. (323.66%), less than Exelixis, Inc. (21.26%), less than Halozyme Therapeutics, Inc. (156.40%), greater than Legend Biotech Corporation (-29.69%), greater than Zai Lab Limited (-36.97%), less than Ascendis Pharma A/S (212.63%), less than Incyte Corporation (0.78%), less than United Therapeutics Corporation (19.22%), greater than Ultragenyx Pharmaceutical Inc. (-187.12%), greater than Apellis Pharmaceuticals, Inc. (-103.92%), greater than Viking Therapeutics, Inc. (-12.73%), greater than TG Therapeutics, Inc. (-8.32%), greater than X4 Pharmaceuticals, Inc. (-32.51%), greater than PDS Biotechnology Corporation (-139.57%), greater than Madrigal Pharmaceuticals, Inc. (-71.78%), greater than IVERIC bio, Inc. (-39.26%), greater than Immunovant, Inc. (-56.40%), greater than Akero Therapeutics, Inc. (-32.52%),
Company | ROE | Market cap |
---|---|---|
6.22% | $12.25B | |
323.66% | $31.59B | |
21.26% | $10.17B | |
156.40% | $6.23B | |
-29.69% | $7.51B | |
-36.97% | $2.97B | |
212.63% | $7.76B | |
0.78% | $13.82B | |
19.22% | $16.65B | |
-187.12% | $4.36B | |
-103.92% | $3.83B | |
-12.73% | $5.86B | |
-8.32% | $5.46B | |
-32.51% | $57.64M | |
-139.57% | $78.19M | |
-71.78% | $7.58B | |
-39.26% | $5.51B | |
-56.40% | $3.94B | |
-32.52% | $2.28B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Seagen Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Seagen Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Seagen Inc.'s ROE?
How is the ROE calculated for Seagen Inc. (SGEN)?
What is the highest ROE for Seagen Inc. (SGEN)?
What is the 3-year average ROE for Seagen Inc. (SGEN)?
What is the 5-year average ROE for Seagen Inc. (SGEN)?
How does the current ROE for Seagen Inc. (SGEN) compare to its historical average?